Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction.
Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction.
复制标题
DOI：
10.1016/j.amjcard.2022.04.031
复制
发表时间：
2022-08-01
影响因子：
2.8
通讯作者：
Hiebert, John B.
中科院分区：
文献类型：
--
作者：
Pierce, Janet D.;Shen, Qiuhua;Mahoney, Diane E.;Rahman, Faith;Krueger, Kathryn J.;Diaz, Francisco J.;Clark, Lauren;Smith, Carol;Vacek, James;Hiebert, John B.
射血分数保留(HFpEF)的心力衰竭患者很少有药物治疗，补充泛喹酚和/或d-核糖是否能改善预后尚不清楚。这项研究的总体目标是确定泛喹酚和/或d-核糖是否能减轻HFpEF患者的症状并改善其心功能。这是一项2期随机、双盲、安慰剂对照试验，涉及216名50岁的≥患者，他们的左心室射血分数(EF)≥为50%。共有4个研究组在12周内接受了不同的补充剂：第一组服用安慰剂泛喹酚胶囊和d-核糖粉，第二组服用泛喹酚胶囊(600 mg/d)和安慰剂d-核糖粉，第三组服用安慰剂泛喹酚胶囊和d-核糖粉(15g/d)，以及第四组服用泛喹酚胶囊和d-核糖粉。本研究有7项观察指标：堪萨斯城心肌病问卷(KCCQ)临床总分、心境状态子量表的活力水平、EF、二尖瓣充盈早期峰值速度与舒张期早期二尖瓣环血流速度的比率(E/e‘比率)、B型利钠肽、乳酸/三磷酸腺苷比率和6分钟步行试验。泛喹酚和/或d-核糖治疗可显著改善KCCQ临床总分(17.30~25.82分)、活力评分(7.65~8.15分)和EF(7.08%~8.03%)，降低B型利钠肽(−72.02~−47.51)和乳酸/三磷酸腺苷比值(−4.32~−3.35×10−4)。间隔E/E‘或6分钟步行试验无明显增加。综上所述，泛喹酚和d-核糖可减轻HFpEF的症状，提高EF。这些发现支持在对HFpEF患者进行标准治疗的同时使用这些补充剂。
Patients with heart failure with preserved ejection fraction (HFpEF) have few pharmacologic therapies, and it is not known if supplementing with ubiquinol and/or d-ribose could improve outcomes. The overall objective of this study was to determine if ubiquinol and/ or d-ribose would reduce the symptoms and improve cardiac performance in patients with HFpEF. This was a phase 2 randomized, double-blind, placebo-controlled trial of 216 patients with HFpEF who were ≥ 50 years old with a left ventricular ejection fraction (EF) ≥ 50%. A total of 4 study groups received various supplements over 12 weeks: Group 1 received placebo ubiquinol capsules and d-ribose powder, Group 2 received ubiquinol capsules (600 mg/d) and placebo d-ribose powder, Group 3 received placebo ubiquinol capsules with d-ribose powder (15 g/d), and Group 4 received ubiquinol capsules and d-ribose powder. There were 7 outcome measures for this study: Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, level of vigor using a subscale from the Profile of Mood States, EF, the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity (septal E/e’ ratio), B-type natriuretic peptides, lactate/adenosine triphosphate ratio, and the 6-minute walk test. Treatment with ubiquinol and/or d-ribose significantly improved the KCCQ clinical summary score (17.30 to 25.82 points), vigor score (7.65 to 8.15 points), and EF (7.08% to 8.03%) and reduced B-type natriuretic peptides (−72.02 to −47.51) and lactate/adenosine triphosphate ratio (−4.32 to −3.35 × 10 −4). There were no significant increases in the septal E/e’ or the 6-minute walk test. In conclusion, ubiquinol and d-ribose reduced the symptoms of HFpEF and increased the EF. These findings support the use of these supplements in addition to standard therapeutic treatments for patients with HFpEF.
登录
查看更多内容
影响因子：
3
作者：
Samuel TY;Hasin T;Gotsman I;Weitzman T;Ben Ivgi F;Dadon Z;Asher E;Amir O;Glikson M;Alcalai R;Leibowitz D
通讯作者：
Leibowitz D
影响因子：
5.6
作者：
Roell KR;Reif DM;Motsinger-Reif AA
通讯作者：
Motsinger-Reif AA
影响因子：
2.3
作者：
Bayram M;St Cyr JA;Abraham WT
通讯作者：
Abraham WT
影响因子：
3.7
作者：
Chida J;Ono R;Yamane K;Hiyoshi M;Nishimura M;Onodera M;Nakataki E;Shichijo K;Matushita M;Kido H
通讯作者：
Kido H
影响因子：
3.8
作者：
Huang W;Teng TK;Tay WT;Richards AM;Kadam U;Lawson CA;Shimizu W;Loh SY;Anand I;Lam CSP
通讯作者：
Lam CSP